Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. - Wikidata - wikimedia - TriplyDB

Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass.

Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass.

http://www.wikidata.org/entity/Q37670181

about

Effects of GLP-1 on appetite and weight Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia β-cell function after weight-loss induced by bariatric surgery.Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion Bariatric surgery and obesity: influence on the incretins Roux-en-Y gastric bypass does not affect daily water intake or the drinking response to dipsogenic stimuli in rats Recent advances in clinical practice challenges and opportunities in the management of obesity.The physiology underlying Roux-en-Y gastric bypass: a status report.GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass?Roux-en-Y gastric bypass: limb length and weight loss.Accurate Measurement of Postprandial Glucose Turnover: Why Is It Difficult and How Can It Be Done (Relatively) Simply?Defective Glucagon-Like Peptide 1 Secretion in Prediabetes and Type 2 Diabetes Is Influenced by Weight and Sex. Chicken, Egg, or None of the Above?Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.A global perspective for managing obesity and improving health: conventional treatment and surgical options: 4th Annual Obesity Summit, London, April 2016.Improvements in the metabolic milieu following Roux-en-Y gastric bypass and the arrest of diabetic kidney disease.Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency.GLP-1: a mediator of the beneficial metabolic effects of bariatric surgery?Diabetes after Bariatric Surgery.Physiological and molecular responses to bariatric surgery: markers or mechanisms underlying T2DM resolution?Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery Roux-en-Y gastric bypass reduces lipid overaccumulation in liver by upregulating hepatic autophagy in obese diabetic rats.Roux-en-Y Gastric Bypass Improves Hepatic Glucose Metabolism Involving Down-Regulation of Protein Tyrosine Phosphatase 1B in Obese Rats.The role of glucagon in weight loss-mediated metabolic improvement: a systematic review and meta-analysis.Early Weight Loss Independent Effects of Sleeve Gastrectomy on Diet-Induced Cardiac Dysfunction in Obese, Wistar Rats.Glucose Metabolism After Gastric Banding and Gastric Bypass in Individuals With Type 2 Diabetes: Weight Loss Effect.The Gastrointestinal Tract as an Integrator of Mechanical and Hormonal Response to Nutrient Ingestion.Hyperinsulinemic hypoglycemia after gastric bypass surgery: what's up and what's down?Deficient Endogenous Glucose Production During Exercise After Total Pancreatectomy/Islet Autotransplantation.Glucose metabolism during rotational shift-work in healthcare workers.Effects on GLP-1, PYY, and leptin by direct stimulation of terminal ileum and cecum in humans: implications for ileal transposition.Exocrine and Endocrine Interactions in Cystic Fibrosis: A Potential Key to Understanding Insulin Secretion in Health and Disease?Does the hepatic branch of vagus mediate the secretion of glucagon-like peptide-1 during the Roux-en-Y gastric bypass surgery?Takeda G Protein-Coupled Receptor 5-Mechanistic Target of Rapamycin Complex 1 Signaling Contributes to the Increment of Glucagon-Like Peptide-1 Production after Roux-en-Y Gastric Bypass.What Has Bariatric Surgery Taught Us About the Role of the Upper Gastrointestinal Tract in the Regulation of Postprandial Glucose Metabolism?Weight-Independent Mechanisms of Glucose Control After Roux-en-Y Gastric Bypass

P2860

Q27011627-2174E6A2-6F2C-43D1-8EFC-7E358ACF4852 Q27027920-98214D2E-8708-40C2-8891-9FD4C11195AF Q28080912-5C147110-B71D-442F-B83D-DAC85ECA5B5A Q33682506-17DF699F-5A93-4ADA-86E9-111ED4AB4E75 Q33816658-27A21D7F-2EDB-46F3-8E5D-37D8D7821A79 Q33829210-A80D4E74-1ADB-4F9F-A49A-499B5C6CC6A5 Q33838154-78FC57BF-4A4B-4550-9677-3BCAD88F9105 Q33912979-5FDB5DF3-8FC5-464F-A7E4-4A15AC9E1228 Q34219768-BD785BB9-4145-47CF-ABE8-754ABFE90047 Q35043446-045E0AA9-90DE-4EA1-9675-79AD737DB92D Q35360690-9AD6B87B-BC1F-4AD0-880D-2E65428DF930 Q36163431-5E062C50-5D12-48A8-B4BD-BEC3259472DD Q36550772-6133E559-D553-4901-8E1F-721F5884AF25 Q36820759-B6AAEABA-EA9B-4EA6-AE21-782DBDE0503B Q36926350-DEC6A9D6-763B-41A7-BA1C-043AFE54C0C3 Q37212797-9698B4CB-4324-45FB-A95D-32D932EF1A95 Q37575821-2C32DFF1-F7E6-4552-BACB-FEF4702B244E Q37591864-2A5B1BB8-EE2E-48D5-92AB-70717C3DD70F Q38236210-8B1FE810-0681-4279-9D95-28BCA002DE4E Q38270358-8BC0B13A-51FA-4740-A7BF-EC8FEC6934D7 Q38307449-A032DFAA-6983-4CA5-A319-456430DFFCC3 Q38812184-00ECFC32-9ABE-4F37-8D83-F1EDCB29FAEE Q38965089-F2D8558A-6C44-45CD-AFBE-D05954501988 Q39047697-7A735F41-CC68-4C12-9AFA-A045FD2315F0 Q42141028-7EAEC476-F425-4964-89F7-D75374F8F302 Q46707063-CB943FD4-78B7-4747-8404-A8900CFC7756 Q47120332-7E6D9EC6-BCA7-4481-9CBE-EB7198714362 Q47176353-E792D04D-880C-4311-BB89-2956FA921B08 Q47228255-48220E22-41EF-4827-B77A-ABA0BC6D48E5 Q47249342-115BC9B5-2A40-4A47-AE7B-524AAF0F931F Q48143632-DE42F219-A8DB-4367-AF00-E0376C695B6B Q48564573-425DA96C-CAA0-4B0E-A973-4FD31018D28B Q50088175-9A862DAF-911C-47FD-B872-239FA225D4BA Q50618539-22CABDA2-88A5-4BB6-A727-3D1F6070BD87 Q50683780-F2E1FFF1-9616-4FD5-A9C5-D108C4231428 Q51070875-EDFE2DEC-F07A-4ABD-BA12-25B5FF758AB0 Q51316347-0A3CC879-0F3F-40EE-9926-10FC1BC3EAFA Q55363824-6A91E549-762C-43F8-9867-032466EFEEDD Q55555487-C0165C73-DEC8-4C05-8722-39A21E0F73DF Q57108626-D2E62B9B-469F-4A4F-9DA9-9D21675B8ED1

P2860

Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass.

http://www.wikidata.org/entity/Q37670181

description

2013 թվականի հոկտեմբերի 2-ին հրատարակված գիտական հոդված

@hy

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

name

Contribution of endogenous glu ...... fter Roux-en-Y gastric bypass.

@en

Contribution of endogenous glu ...... fter Roux-en-Y gastric bypass.

@nl

type

label

Contribution of endogenous glu ...... fter Roux-en-Y gastric bypass.

@en

Contribution of endogenous glu ...... fter Roux-en-Y gastric bypass.

@nl

prefLabel

Contribution of endogenous glu ...... fter Roux-en-Y gastric bypass.

@en

Contribution of endogenous glu ...... fter Roux-en-Y gastric bypass.

@nl

P1433

Q37670181-58BBE6F4-CC78-4890-B981-2A460789E5DB

P1476

Q37670181-291CCEBC-1A9E-40F0-BCA0-A4C9E498232A

P2093

Q37670181-75E3B595-C87B-4D36-ADF1-714E0303E854

Q37670181-763CE4BB-50CD-42D3-BE06-4E900A04E9D4

Q37670181-7E24DE90-DC47-4CF6-9253-3A73D104C5F7

Q37670181-8F88C8A3-1F27-4968-A4C4-5534349C4BC8

Q37670181-9E46DCE9-5EE8-4F06-861D-EF21124697A3

Q37670181-E9B8B63D-B1AF-4EED-A75D-9DD6EC79B312

P2860

Q37670181-025CFEBB-86BD-4156-BFE8-F047F05DC90A

Q37670181-02F200F2-43C4-4A15-A328-42EBD015157E

Q37670181-07276F6A-5152-460A-B956-B2B374249D00

Q37670181-089310FE-0C41-4851-BDF2-3318E6E47CB7

Q37670181-0F50B264-D70E-48CD-8D85-866117A7A98B

Q37670181-20C52956-5DC2-407D-B7F4-73C4E60EC962

Q37670181-24261EC4-5618-4E8B-8DDA-4137542C353C

Q37670181-3CEAFD5E-D534-4FD7-9FFA-949EAF688368

Q37670181-4B18B1DE-5B1F-48C0-88DE-9D39D4118241

Q37670181-4EF6ECA7-AC13-4CF2-AF06-DF53D463C818

P304

Q37670181-C68B78A5-7B44-4943-B2BF-7D629BFC484D

P31

Q37670181-D8FD4405-0FDA-4B22-BDA3-00A927D93C23

P356

Q37670181-CEA4628F-012E-4773-B716-B50D0C617954

P407

Q37670181-CF189E2D-0338-4A1D-B9EC-84157AF0E9DC

P433

Q37670181-2F3AA577-C97E-4A62-98AE-66A85F763BCD

P478

Q37670181-221EB1CE-197D-490C-89C9-418DC754FDAB

P50

Q37670181-18E9B132-E3D4-4CBE-BBA4-D41C214821A6

Q37670181-5A309369-F733-4B1C-A1B9-2F4208BED625

Q37670181-BA0F03E7-8FDD-410C-AC4A-99D7A85B6F5C

Q37670181-FCF4C7CD-46A3-4B75-B612-A40675008622

P577

Q37670181-ABCCF54B-95C9-4017-98D6-8225F67168D4

P5875

Q37670181-C83C8E47-E8C7-48C4-B3A5-A1F33E885B76

P698

Q37670181-75C95DEF-7955-4116-9CCB-5297FCDCFE79

P921

Q37670181-0FFE3AD1-C015-4A70-92D3-75A146B3F9D0

Q37670181-579e6c48-dd4e-4de1-ba77-8d2624b0009d

P932

Q37670181-CB118853-87C7-4407-848E-A18D3BA46983

P356

P1433

P1476

Contribution of endogenous glu ...... fter Roux-en-Y gastric bypass.

@en

P2093

Adrian Vella

http://www.w3.org/2001/XMLSchema#string

Francesco Micheletto

http://www.w3.org/2001/XMLSchema#string

Jennie H Law

http://www.w3.org/2001/XMLSchema#string

Matheni Sathananthan

http://www.w3.org/2001/XMLSchema#string

Meera Shah

http://www.w3.org/2001/XMLSchema#string

Robert A Rizza

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: surgical treatment of obesity

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2

Bariatric surgery: a systematic review and meta-analysis.

Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity.

GLP-1 for type 2 diabetes.

The glucagon-like peptides.

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.

Bariatric surgery versus conventional medical therapy for type 2 diabetes.

P304

483-493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB13-0954

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Claudio Cobelli

Chiara Dalla Man

Alan R. Zinsmeister

Michael Camilleri

P577

2013-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257310372

http://www.w3.org/2001/XMLSchema#string

P698

24089513

http://www.w3.org/2001/XMLSchema#string

P921

P932

3968439

http://www.w3.org/2001/XMLSchema#string